Hitachi Chemical to acquire apceth Biopharma

5 Feb 2019

Acquisition will strengthen Hitachi's presence in the second-largest cell and gene therapy market in the world.

apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, has announced that Hitachi Chemical will enter into an agreement to acquire all shares of apceth Biopharma GmbH. This acquisition is expected to close in April 2019.

Hitachi Chemical to acquire apceth Biopharma

Founded 2007, apceth is a pioneer in cell and gene therapy and has developed into a leading European CDMO for advanced therapy medicinal products (ATMPs). The company has state-of-the-art facilities located in Munich, Germany, which are fully compliant with all current EU ATMP regulations, BSL2 and ICH guidelines.

With the acquisition of apceth, Hitachi Chemical will be expanding its business presence footprint in Europe ― the world’s second-largest market for regenerative medicine after the US.

“We are very pleased to become part of Hitachi Chemical. Our combined strengths within Hitachi Chemical will allow us to manufacture complex cell and gene therapies for clients in North America, Asia, and Europe. This will allow our clients to supply patients around the world with highly needed innovative and high-quality cell and gene therapies”, said Christine Guenther, CEO of apceth Biopharma.

“apceth had been built by a great team and strong support of its shareholders into Europe’s leading independent cell therapy manufacturer. We are very proud that these joint efforts resulted in apceth Biopharma now being chosen as Hitachi Chemical’s hub for cell therapy in Europe,” commented Manfred Ruediger, Chairman of the Board of apceth.

“We are proud having been able to accompany apceth on its successful journey from its foundation in 2007 until today. We are very pleased to have found an excellent partner for apceth’s future endeavors with Hitachi Chemical,” said Helmut Jeggle, Managing Director of Santo Holding (Deutschland) GmbH, majority shareholder of apceth.

“The addition of apceth Biopharma to Hitachi Chemical will strengthen our presence in the second-largest cell and gene therapy market in the world, and enable us to offer a truly harmonized global operation, providing our customers with ready access to new markets and maximizing the value we bring to the industry,” said Robert A. Preti, PhD, CEO and President of Hitachi Chemical Advanced Therapeutics Solutions, LLC and General Manager of the Hitachi Chemical Regenerative Medicine Business Sector.

Read More

Related news

Vetter's Skokie facility expansion nears completion

Vetter's Skokie facility expansion nears completion

17 Apr 2019

Expansions will help meet an increase in customer projects; a second extension is in the final planning stage.

Read more 
Catalent to acquire gene therapy leader Paragon Bioservices

Catalent to acquire gene therapy leader Paragon Bioservices

16 Apr 2019

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.

Read more 
Colorcon expands functional film coatings through the CR Alliance with DuPont

Colorcon expands functional film coatings through the CR Alliance with DuPont

15 Apr 2019

The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Exploristics surges ahead with £1m investment

Exploristics surges ahead with £1m investment

15 Apr 2019

The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.

Read more 
Catalent celebrates opening of second Shanghai facility

Catalent celebrates opening of second Shanghai facility

14 Apr 2019

Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.

Read more 
Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

12 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more